prikaz prve stranice dokumenta Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry
  Preuzmi
PDF 490.98 KB
Znanstveni rad - Izvorni znanstveni rad
Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry
Hellenic Journal of Cardiology, 62 (2021), 2; 152-157. https://doi.org/10.1016/j.hjc.2020.11.009
(GLORIA-AF) Ntaios, George; ...; Kes, Vanja Basic; Kalan, Marica Bracic; Brkljacic, Diana Delic; Knezevic, Aleksandar; Kovacic, Dragan; Nazlić, Jurica; Persic, Viktor; Pivac, Nediljko; Poljakovic, Zdravka

Citirajte ovaj rad

Ntaios, G., Kes, V. B., Kalan, M. B., Brkljacic, D. D., Knezevic, A., Kovacic, D. ... Poljakovic, Z. (2021). Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry. Hellenic Journal of Cardiology, 62. (2), 152-157. doi: 10.1016/j.hjc.2020.11.009

Ntaios, George, et al. "Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry." Hellenic Journal of Cardiology, vol. 62, br. 2, 2021, str. 152-157. https://doi.org/10.1016/j.hjc.2020.11.009

Ntaios, George, Vanja Basic Kes, Marica Bracic Kalan, Diana Delic Brkljacic, Aleksandar Knezevic, Dragan Kovacic, Jurica Nazlić, Viktor Persic, Nediljko Pivac i Zdravka Poljakovic. "Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry." Hellenic Journal of Cardiology 62, br. 2 (2021): 152-157. https://doi.org/10.1016/j.hjc.2020.11.009

Ntaios, G., et al. (2021) 'Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry', Hellenic Journal of Cardiology, 62(2), str. 152-157. doi: 10.1016/j.hjc.2020.11.009

Ntaios G, Kes VB, Kalan MB, Brkljacic DD, Knezevic A, Kovacic D, i sur.. Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry. Hellenic Journal of Cardiology [Internet]. 03.2021. [pristupljeno 26.06.2024.];62(2):152-157. doi: 10.1016/j.hjc.2020.11.009

G. Ntaios, et al., "Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry", Hellenic Journal of Cardiology, vol. 62, br. 2, str. 152-157, Ožujak 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:220:642947. [Citirano: 26.06.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:220:642947
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry
AutorGeorge Ntaios
Autor
...
AutorVanja Basic Kes
AutorMarica Bracic Kalan
AutorDiana Delic Brkljacic
AutorAleksandar Knezevic
AutorDragan Kovacic
AutorJurica Nazlić
AutorViktor Persic
AutorNediljko Pivac
AutorZdravka Poljakovic
KolaboracijaGLORIA-AF
Autorova ustanova(Klinički bolnički centar Sestre milosrdnice)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anti-coagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and 1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores 2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anti-coagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaHellenic Journal of Cardiology
Brojčani podacivol. 62, br. 2, str. 152-157
p-ISSN1109-9666
DOIhttps://doi.org/10.1016/j.hjc.2020.11.009
URN:NBNurn:nbn:hr:220:642947
Datum objave publikacije2021-03
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S1109966620302815
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-06-25 11:34:51